Crossroads Venture Group
Presented by: Crossroads Venture Group & CURE
Supporting Organization: BEACON
Crossroads Venture Group is sponsored by:
Fiondella Milone & LaSaracina, Mintz + Hoke, Murtha Cullina, PricewaterhouseCoopers, Robinson & Cole, Shipman & Goodwin, Updike, Kelly & Spellacy, P.C., Wiggin and Dana, Webster Bank, CCEI - University of Connecticut, Connecticut Innovations, Economic Development Corporation of New Haven, TriNet HR Corporation, Yale University - Office of Cooperative Research, Advantage Capital, Canaan Partners, Cava Capital, Enhanced Capital, LaunchCapital LLC, Stonehenge Growth Capital, Ambrose Employer Group LLC, Carter Morse & Mathias, CohnReznick LLP, Fairfield Partners Executive Search, Hanover Insurance Group, O'Connor Davies LLC, Pullman and Comley LLC
Challenges and strategies of medical devices companies in 2014.
A panel of experts will consider current topics impacting the challenges and strategies of medical device companies in 2014. We will learn how device companies are effectively building their pipelines using innovative intellectual property strategies and overcoming new regulatory hurdles. Additionally the panel will offer insight into how investors are evaluating opportunities and where they see significant trends in the industry heading. This will be an interactive session with time for Q &A from an experienced group of knowledgeable specialists.
Paul Hermes, Entrepreneur in Residence, Covidien
Margaret Cartiera, Director, Connecticut Innovations
Glenn Gibbons, Senior Director, Covidien
Basam Nabulsi, Managing Partner, McCarter & English
(Full bio's featured below)
Paul Hermes is an Entrepreneur In Residence within Covidien’s Surgical Solutions Global Business Unit. Prior to his appointment, Paul served as Chief Technology Officer for Covidien’s Medical Devices segment after managing the R&D functions of the Surgical Devices and Energy-based Devices global business units. Since joining the Company in 1991, he has significantly impacted the surgical devices market, overseeing the launch of the TriStaple™, iDrive™, SILS™, AbsorbaTack™ and LigaSure™ product lines. He has been instrumental in revitalizing the company’s product portfolio, and established Covidien’s first innovation footprint in India and China.
Margaret Cartiera supports the initiation and management of the Connecticut Bioscience Innovation Fund and other bioscience initiatives at CT Innovations. Margaret is trained as a biomedical engineer and has expertise in regulatory affairs, competitive intelligence, market research and operational management. She has more than 15 years of experience in the investment, medical device, pharmaceutical and biotech fields, having worked for companies both large and small, such as Siemens Medical Systems and Carigent Therapeutics.
Glenn Gibbons has been with Covidien for five years where he is responsible for strategy, portfolio and business development as a Senior Director. Gibbons is also on the leadership team for Covidien’s General Surgical Products Division and is working to grow the company, inorganically, through mergers and acquisitions. Previously, Gibbons worked at GE Healthcare Financial Services where he was Vice President of Business Development for three years. Gibbons has an MBA in finance from Fairfield University and a bachelor’s in accounting from Johnson and Wales.
Basam Nabulsi is the Managing Partner of McCarter & English’s Stamford office where he focues on intellectual property issues and patent law. His clients include numerous industrial/manufacturing companies, universities and entrepreneurial ventures. He has expertise with technologies that draw on the fields of chemical engineering, mechanical engineering and electromechanical engineering as well as patents and software-based technologies. He represents numerous clients in the medical device field as well as several universities/technology transfer offices.
IMPORTANT NOTICE TO PRESENTING COMPANIES:
The Securities and Exchange Commission has adopted new rules that can complicate private placements and what a company can and cannot say during events such as Crossroads Venture Group sponsored events. A presentation at such an event could constitute a “general solicitation,” which could add complications and cost to compliance with applicable securities laws. Therefore, presenting companies must consult with experienced legal counsel prior to speaking at any such event. By presenting at a Crossroads Venture Group event, each presenting company acknowledges that (i) it is their responsibility to ensure compliance with applicable securities laws, including the content of its presentation, the making of appropriate regulatory filings and the inclusion of appropriate disclaimers and legends on it's presenting material, and (ii) neither the Crossroads Venture Group nor any of its representatives is responsible for any such compliance.